Not medical advice. This website is not medical advice, a diagnosis, a match to a trial, or a recommendation to join a study. Listings are plain-English rewrites of public ClinicalTrials.gov records. Whether a site is still enrolling, and whether you qualify, can only be confirmed by the study team and your clinician. Source registry: ClinicalTrials.gov. Editorial rules: methodology.
PlainTrials
RecruitingNot a traditional drug phaseinterventionalRules rewrite

Not a traditional drug phase: Exercise for Cirrhosis With Hepatocellular Carcinoma

The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma. The effect of exercise on hepatokines and metabolites production in liver cancer patients is not known.

Official registry: https://clinicaltrials.gov/study/NCT07189624 · University Hospital, Clermont-Ferrand · enrollment listed as 12

What this phase means

This study does not use the classic phase 1–4 drug ladder. It may be a device, a behavior program, a surgery timing study, or an early feasibility test.

Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

What the registry says happens

If you join, the listed intervention(s) are Exercise. The registry lists allocation as na. The main purpose of the study is to characterize the production of hepatokines (FGF21 and Follistatin) in response to a submaximal exercise on an ergocycle, in patients with hepatocellular carcinoma.

They plan to enroll about 12 people at 2 sites. Taking part typically means study visits and measurements plus check-ins.

Official title (unrewritten)

Effect of Acute Endurance Exercise on the Production of FGF21 and Follistatin in Patients With Hepatocellular Carcinoma

Interventions: Exercise

Primary outcome (registry wording): Systemic hepatokines rates (FGF-21 and follistatin)

Who it is for (from inclusion criteria)

  • Ages 18 Years to 80 Years
  • Hepatocellular carcinoma developed on cirrhosis
  • Cirrhosis of any etiology, defined by a liver elasticity measurement \>15kPa or a history of cirrhosis decompensation
  • Hepatocellular carcinoma with indication for treatment by immunotherapy or chemoembolization
  • Child-Pugh scores A and B7
  • Affiliation to french national social security system

Public study contact (from the registry)

Lise Laclautre

0473754963

promo_interne_drci@chu-clermontferrand.fr

Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.

Sites listed on ClinicalTrials.gov

2 listed

Related recruiting trials in this snapshot

FAQ about this NCT record

Is NCT07189624 still recruiting?

The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.

What phase is NCT07189624?

Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.

Can PlainTrials tell me if I qualify for NCT07189624?

No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.

How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary